comparemela.com

Latest Breaking News On - Michel janicot - Page 1 : comparemela.com

Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Ymmunobio Appoints Dr Michel Janicot as Chief Development Officer

Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

Synthetic microRNA can serve as a novel therapeutic agent for treating human cancer

Oncotarget published "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology" which reported that the authors comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic

Oncotarget: 1B3 supports strong potential for therapeutic intervention in oncology

Interestingly, the exact mechanism through which 1B3 reduced cell proliferation varied between cell lines. 1B3 efficiently reduced target gene expression, leading to reduced cell proliferation/survival, cell cycle arrest, induction of apoptosis, increased cell senescence, DNA damage, and inhibition of migration. SiRNA silencing of 1B3 target mRNAs further highlighted the advantage of the pleiotropic mechanism of 1B3 action, as repression of individual targets did not achieve the same robust effect on cell proliferation in all cell lines. Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer. Dr. Michel Janicot from InteRNA Technologies BV said,

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.